Research Highlights on Pyruvate Kinase (PK) Deficiency

This accredited CME activity provides a summary of the latest information about Pyruvate kinase (PK) deficiency that was presented at the 2021 American Society of Hematology Annual Meeting (ASH 2021). Since the Covid-19 pandemic limited the ability for specialists to attend ASH 2021 and discuss this latest research, this program provides a review by Rachael Grace, MD, of the most clinically-relevant information on PK deficiency presented during the meeting.

PK deficiency is a rare genetic blood disorder characterized by low levels of the enzyme pyruvate kinase, which interrupts the glycolytic pathway causing hemolytic anemia. The degree of hemolysis is variable, ranging from mild forms of PK deficiency to life-threatening neonatal anemia that require exchange transfusions and subsequent continuous transfusion support. Both hematologists and generalists who may be involved in the care of patients with PK deficiency may benefit from learning the latest information about this rare disease, and its implications for patient care.